The START Study to evaluate the effectiveness of a combination intervention package to enhance antiretroviral therapy uptake and retention during TB treatment among TB/HIV patients in Lesotho: rationale and design of a mixed-methods, cluster-randomized trial

Background Initiating antiretroviral therapy (ART) early during tuberculosis (TB) treatment increases survival; however, implementation is suboptimal. Implementation science studies are needed to identify interventions to address this evidence-to-program gap. Objective The Start TB Patients on ART and Retain on Treatment (START) Study is a mixed-methods, cluster-randomized trial aimed at evaluating the effectiveness, cost-effectiveness, and acceptability of a combination intervention package (CIP) to improve early ART initiation, retention, and TB treatment success among TB/HIV patients in Berea District, Lesotho. Design Twelve health facilities were randomized to receive the CIP or standard of care after stratification by facility type (hospital or health center). The CIP includes nurse training and mentorship, using a clinical algorithm; transport reimbursement and health education by village health workers (VHW) for patients and treatment supporters; and adherence support using text messaging and VHW. Routine data were abstracted for all newly registered TB/HIV patients; anticipated sample size was 1,200 individuals. A measurement cohort of TB/HIV patients initiating ART was recruited; the target enrollment was 384 individuals, each to be followed for the duration of TB treatment (6–9 months). Inclusion criteria were HIV-infected; on TB treatment; initiated ART within 2 months of TB treatment initiation; age ≥18; English- or Sesotho-speaking; and capable of informed consent. The exclusion criterion was multidrug-resistant TB. Three groups of key informants were recruited from intervention clinics: early ART initiators; non/late ART initiators; and health care workers. Primary outcomes include ART initiation, retention, and TB treatment success. Secondary outcomes include time to ART initiation, adherence, change in CD4+ count, sputum smear conversion, cost-effectiveness, and acceptability. Follow-up and data abstraction are complete. Discussion The START Study evaluates a CIP targeting barriers to early ART implementation among TB/HIV patients. If the CIP is found effective and acceptable, this study has the potential to inform care for TB/HIV patients in high-burden, resource-limited countries in sub-Saharan Africa.

[1]  A. Strauss,et al.  Grounded theory , 2017 .

[2]  S. Rosen,et al.  Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008–2013 , 2015, Journal of acquired immune deficiency syndromes.

[3]  F. J. Fowler,et al.  Cognitive and Field Testing of a New Set of Medication Adherence Self-Report Items for HIV Care , 2013, AIDS and Behavior.

[4]  Russell E. Glasgow,et al.  Implementation Science Perspectives and Opportunities for HIV/AIDS Research: Integrating Science, Practice, and Policy , 2013, Journal of acquired immune deficiency syndromes.

[5]  M. van Lettow,et al.  Reasons for accepting or refusing HIV services among tuberculosis patients at a TB-HIV integration clinic in Malawi. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[6]  Anneke Grobler,et al.  Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.

[7]  Lerato Mohapi,et al.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.

[8]  S. Vong,et al.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.

[9]  S. Lawn,et al.  Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township , 2011, BMC infectious diseases.

[10]  D. Gareta,et al.  Timing and uptake of ART during treatment for active tuberculosis in HIV co-infected adults in Malawi. , 2011, Public health action.

[11]  Charles B Holmes,et al.  Implementation Science for the US President's Emergency Plan for AIDS Relief (PEPFAR) , 2011, Journal of acquired immune deficiency syndromes.

[12]  S. Lawn,et al.  Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections , 2011, Current opinion in infectious diseases.

[13]  V. Bond,et al.  Barriers and outcomes: TB patients co-infected with HIV accessing antiretroviral therapy in rural Zambia , 2010, AIDS care.

[14]  D. Kuritzkes,et al.  Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  S. Lawn,et al.  The HIV-associated tuberculosis epidemic—when will we act? , 2010, The Lancet.

[16]  F. Varaine,et al.  Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  A. Hurtig,et al.  Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon , 2010, BMC public health.

[18]  S. Lawn,et al.  Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-Limited Settings , 2009, Clinics in chest medicine.

[19]  P. Fujiwara,et al.  Health system barriers affecting the implementation of collaborative TB-HIV services in Uganda. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  U. Lalloo,et al.  Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa: The Sizonq'oba Study , 2009, Journal of acquired immune deficiency syndromes.

[21]  G. Rutherford,et al.  Oral manifestations of HIV infection in patients receiving highly active antiretroviral therapy (HAART) in Bahia, Brazil. , 2008, Journal of public health dentistry.

[22]  J. Durlak,et al.  Implementation Matters: A Review of Research on the Influence of Implementation on Program Outcomes and the Factors Affecting Implementation , 2008, American journal of community psychology.

[23]  Krista L. Dong,et al.  Challenges to the success of HIV and tuberculosis care and treatment in the public health sector in South Africa. , 2007, The Journal of infectious diseases.

[24]  S. Kalichman,et al.  Adherence to Antiretroviral Therapy Assessed by Unannounced Pill Counts Conducted by Telephone , 2007, Journal of General Internal Medicine.

[25]  A. Harries,et al.  Acceptance of Anti-Retroviral Therapy among Patients Infected with HIV and Tuberculosis in Rural Malawi Is Low and Associated with Cost of Transport , 2006, PloS one.

[26]  John W. Creswell,et al.  Designing and Conducting Mixed Methods Research , 2006 .

[27]  L. Myer,et al.  Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control , 2006, AIDS.

[28]  Icf Macro,et al.  Lesotho Demographic and Health Survey 2009 , 2005 .

[29]  Jonathan L. Blitstein,et al.  Design and analysis of group-randomized trials: a review of recent methodological developments. , 2004, American journal of public health.

[30]  A. Harries,et al.  Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa , 2001, AIDS.

[31]  M. Patton,et al.  Enhancing the quality and credibility of qualitative analysis. , 1999, Health services research.

[32]  H. Snyder.  Qualitative interviewing: The art of hearing data , 1996 .

[33]  M. Sandelowski.  Sample size in qualitative research. , 1995, Research in nursing & health.

[34]  O. Aasland,et al.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.

[35]  Valerie J. Caracelli,et al.  Toward a Conceptual Framework for Mixed-Method Evaluation Designs , 1989 .

[36]  Digambar Behera,et al.  Global tuberculosis control 2010 , 2012 .

[37]  Erin Doheny,et al.  United States Agency for International Development , 2011 .

[38]  H. Rubin,et al.  Qualitative Interviewing (2nd ed.): The Art of Hearing Data , 2005 .

[39]  E. Duflo,et al.  Use of Randomization in the Evaluation of Development Effectiveness , 2004 .

[40]  Clive Seale.  Qualitative research practice , 2004 .

[41]  E. Eckert,et al.  Compendium of indicators for monitoring and evaluating national tuberculosis programs. , 2004 .

[42]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[43]  W. Reynolds.  Development of reliable and valid short forms of the marlowe-crowne social desirability scale , 1982 .

[44]  M. Patton.  Qualitative research and evaluation methods , 1980 .